Wyeth Korea to introduce new version of pneumococcal polysaccharide vaccine from this November

Published: 2003-09-09 06:58:00

Updated: 2003-09-09 06:58:00

Wyeth Korea said it would launch from this November a new version of 23-valent pneumococcal polysaccharide vaccine (23PS), Prevnar, or heptavalent pneumococcal conjugate vaccine (PCV7) and can be given to younger children under age 23 months who are at high risk. The vaccine protects against many...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK